Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Teva Pharmaceutical (TEVA)

39.59

+0.06 (0.15%)

as of Oct 5, 2026, 7:17:28 pm Market Open.

71 watching

PAST TOP PICK

(A Top Pick Oct 14/08. Up 23.38%.) World's largest generic drug company. Also have some branded drugs that are doing very well.

COMMENT

Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.)

BUY

World's largest manufacturer of generic drugs. Also has its own patented proprietary drugs. Has grown through acquisitions and by taking advantage of the drugs that are coming off patent.

COMMENT

Likes the generic drug space, especially with the new US administration. There are a lot of moves up in estimates, both quarterly and annual. He also likes Mylan (MYL-Q), which has a little bit more growth and probably cheaper on a PE level.

DON'T BUY

Once generic stocks have their products in place they can milk it for several years to come. He wouldn't be looking at this right now.

PAST TOP PICK

(A Top Pick July 21/08. Up 14.55%.)

TOP PICK

Has 25% of the US generic drug market. Generics will gain with the government’s new health plans. Trades at about 15X earnings. Long record of successfully increasing earnings and dividends.

BUY

Largest generic drug manufacturer globally. Grows through patents coming off existing drugs and by making acquisitions. Have also developed a number of drugs on their own.

TOP PICK

Countries everywhere will be looking at ways of cutting back on drug costs. This is the biggest generic drug company globally. A defensive sector.

TOP PICK

During the bear market decline, this stock held in like a rock. It's both defensive and growth. Selling at less than half of its 30% growth rate. Hitting on all cylinders.

TOP PICK

World's largest drug market and will benefit from US push to lower health care costs. Likes it for growth. Likely to see 30% in short term. Biggest risk is the development of new drug candidates.

TOP PICK

World’s largest generic manufacturer. With their Barr acquisition they now have 25% of the US generic market and 17% of the total prescription market. This is in an era where it looks like the US administration is moving to a more nationalized health care plan

TOP PICK

Worlds largest maker of generic drugs. US administration is likely to push forward towards greater use of generics that would give them a $9.2 billion savings over the next 10 years. This company will be a beneficiary. Made an acquisition last year of Barr Pharmaceuticals, which will give them good synergies.

TOP PICK

Israeli-based pharmaceutical company. Recently completed an acquisition of US Barr Pharmaceuticals giving them the largest share (25%) of the generic market in the US. US healthcare focus on generics is going to increase. Leader in producing new generics and is able to negotiate better prices for its products. Earnings in 2010 are expected to increase by more than 30%. Small but growing dividend.

PAST TOP PICK

(A Top Pick Feb 26/02. Down 10.2%.)

Showing 196 to 210 of 279 entries

Most Recent Experts

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Bruce Murray

The Murray Wealth Group

Dennis Mitchell, CFA

Sentry Select Capital Corp

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)